1. Healthy With HIV

3. This program will include a discussion of data that were presented in abstract form These data should be considered preliminary until published in a peer-reviewed journal

4. Introduction

5. Prevention of Cardiovascular Disease in PLWHIV

6. Challenges in Managing CVD in PLWHIV

7. PLWHIV Are Aging

8. Cardiovascular and Metabolic Complications in PLWHIV

9. PLWHIV Have Higher Rates of CV Risk Factors and Comorbidities

10. Higher Risk of Coronary Artery Disease (Myocardial Infarction)

11. Specific Needs in the Aging HIV population Depending on Gender (Men vs Women)

12. Cessation of Smoking Leads to a Better CV Risk Profile

13. The Risk of MI Decreased With Smoking Cessation in HIV+ DAD Study

14. Hypertension (HTN)

15. Preventing CVD

16. Underused Guideline-Recommended Cardiovascular Care in PLWHIV

17. DDI and Polypharmacy

18. Concluding Remarks

19. Concluding Remarks (cont)

20. Low BMD, Osteoporosis, and Preservation of Bone Health in PLWHIV

21. Why Is Low BMD Important in PLWHIV?

22. Classic Risk Factors for Reduced BMD

23. ART and Low BMD

24. Non-HIV Risk Factors for Fracture

25. Measuring BMD

26. Managing Low BMD

27. Concluding Remarks

28. Renal Impairment in PLWHIV

29. Spectrum of Renal Disease in PLWHIV

30. Spectrum of Renal Disease in PLWHIV (cont)

31. Evolution of Comorbidities Among PLWHIV

32. Risk Factors for CKD in PLWHIV

33. CVD Is a Risk Factor for CKD: Strong Reciprocal Relationship

34. Other Risk Factors for CKD

35. Prevention of Renal Disease

36. Acute Renal Failure

37. Impact of Long-Term cART on Renal Impairment

38. Screening and Diagnosis of Renal Impairment in PLWH

39. Monitoring Renal Function and Pathology: Glomerular Filtration

40. Monitoring Renal Function and Pathology (cont)

41. Monitoring Renal Function and Pathology (cont)

42. Calculating Renal Risk

43. Concluding Remarks

44. Series Conclusion

45. Abbreviations

46. Abbreviations (cont)

47. Abbreviations (cont)

48. Abbreviations (cont)